WO1995010610A1 - POLYPEPTIDES DE BETAGLYCANE DOTES D'UNE ACTIVITE DE FIXATION AU FACTEUR DE CROISSANCE TRANSFORMANT DE TYPE BETA TGF-$g(b) - Google Patents

POLYPEPTIDES DE BETAGLYCANE DOTES D'UNE ACTIVITE DE FIXATION AU FACTEUR DE CROISSANCE TRANSFORMANT DE TYPE BETA TGF-$g(b) Download PDF

Info

Publication number
WO1995010610A1
WO1995010610A1 PCT/US1994/011648 US9411648W WO9510610A1 WO 1995010610 A1 WO1995010610 A1 WO 1995010610A1 US 9411648 W US9411648 W US 9411648W WO 9510610 A1 WO9510610 A1 WO 9510610A1
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
ser
leu
pro
betaglycan
Prior art date
Application number
PCT/US1994/011648
Other languages
English (en)
Other versions
WO1995010610A9 (fr
Inventor
Erkki Ruoslahti
Daikichi Fukushima
Ralf Butzow
Original Assignee
La Jolla Cancer Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Cancer Research Foundation filed Critical La Jolla Cancer Research Foundation
Priority to AU80168/94A priority Critical patent/AU8016894A/en
Publication of WO1995010610A1 publication Critical patent/WO1995010610A1/fr
Publication of WO1995010610A9 publication Critical patent/WO1995010610A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to the field of polypeptides and, in particular, to betaglycan polypeptides that bind to TGF-3.
  • TGF- ⁇ Transforming growth factor-beta
  • TGF- ⁇ Three isoforms of TGF- ⁇ (TGF- ⁇ 1, 2 and 3) are expressed in mammals and to date show similar properties in vitro . Platelets contain high concentrations of TGF- ⁇ , and upon degranulation at a site of injury, release TGF- ⁇ into the surrounding tissue.
  • TGF- ⁇ then initiates a sequence of events that promotes healing including (1) che o-attraction of monocytes, neutrophils, and fibroblasts, (2) auto-induction of TGF- ⁇ production and stimulation of monocytes to secrete interleukin-1 (IL-1), tumor necrosis factor and other cytokines, (3) induction of angiogenesis and cell proliferation, (4) control of inflammation and cell toxicity by acting as a potent immunosuppressant and inhibitor of peroxide release, and (5) increased deposition of extracellular matrix.
  • TGF- ⁇ also induces proliferation of macrophages exposed in combination with macrophage colony stimulating factor ("M-CSF”) or granulocyte macrophage colony stimulating f ctor (“GM-CSF”) .
  • M-CSF macrophage colony stimulating factor
  • GM-CSF granulocyte macrophage colony stimulating f ctor
  • TGF-/3 is associated with pathological scarring and has been implicated in glomerulonephritis, diabetic nephropathy, lung fibrosis, liver cirrhosis, intimal hyperplasia. cardiac cirrhosis after infarct, adult respiratory distress syndrome and other fibrotic pathologies.
  • TGF- ⁇ activity both up and down, has important therapeutic significance.
  • Betaglycan is a transmembrane proteoglycan whose core protein has molecular weight of about 100 kD. The betaglycan core protein binds TGF- ⁇ with high affinity.
  • the betaglycan core protein has 853 a ino acids and consists of four domains.
  • the N-terminal one-third of the extracellular domain and the C-terminal cytoplasmic domain have similarities with endoglin.
  • Endoglin is a TGF-/3 binding protein expressed on the surface of endothelial cells.
  • the middle part of the betaglycan extracellular domain has a short stretch similar to a portion of endoglin but otherwise bears no homology to any known protein.
  • the 260 amino acids in the ectodomain closest to the membrane are related to a domain in a group of transmembrane proteins which include sperm receptors Zp2 and Zp3, the zymogen granule membrane protein, GP2, and uromodulin. This common domain occurs at a similar location relative to the transmembrane domain in these proteins.
  • Betaglycan is the major TGF- ⁇ -binding molecule on most cell types. However, many cell types which respond to TGF- ⁇ , e.g., hematopoietic cells, do not appear to have detectable amounts of betaglycan. This, together with evidence from TGF- ⁇ -resistant mutant cell lines, suggests that betaglycan is not directly involved in the TGF- ⁇ signal transduction pathway. Over- expression of betaglycan in Chinese hamster ovary cells enhances binding of TGF- ⁇ to type II receptor, suggesting that betaglycan acts by stockpiling TGF- ⁇ and presenting it to the signal transducing proteins in the receptor.
  • betaglycan has potential as a modulator of TGF- ⁇ bioactivity.
  • the art does not disclose the portion of betaglycan that has TGF-3 binding activity and that enhances TGF-3 binding to the type II receptor.
  • This invention satisfies this need and provides additional advantages by identifying a portion of betaglycan that binds TGF- ⁇ , enhances TGF- ⁇ binding to the type II receptor and enhances suppression of cell growth by TGF-/3.
  • This invention provides polypeptides of at least 155 amino acids that bind to TGF- ⁇ and that have a sequence consisting essentially of a sequence of a portion of a mammalian betaglycan within about one-third of the extracellular domain closest to the cell membrane. It also provides polypeptides having a sequence consisting essentially of a portion of a mammalian betaglycan wherein the portion is about one-fourth or about one-fifth of the extracellular domain of a mammalian betaglycan closest to the cell membrane. More particularly, it provides polypeptides wherein the sequence consists essentially of at least amino acids 543 to 769 of SEQ ID NO:2 to at most amino acids 501 to 853 of SEQ ID NO:2.
  • This invention also provides a soluble polypeptide having the formula A-B-C, wherein A is a sequence excluding amino acid sequences of more than 4 amino acids from amino acids 1 to 543 of SEQ ID NO:2; B is an amino acid sequence consisting essentially of at least amino acids 543 to 769 of SEQ ID NO:2 to at most amino acids 501 to 769 of SEQ ID NO:2; and C is an amino acid sequence.
  • This invention also provides a soluble polypeptide having the formula A-B-C, wherein A is an amino acid sequence excluding sequences of more than 4 amino acids from amino acids 1 to 543 of SEQ ID NO 2; B is at least 155 amino acids in a sequence consisting essentially of an amino acid sequence within amino acids 543 to 769 of SEQ ID NO:2; and C is an amino acid sequence.
  • This invention also provides isolated nucleic acid molecules encoding any of the polypeptides of this invention, expression vectors having an expression control sequence operatively linked to a nucleic acid molecule of this invention, and prokaryotic or eukaryotic cells transfected with an expression vector of this invention and capable of expressing a nucleic acid of this invention.
  • This invention also provides methods of detecting TGF-/3 in a sample by contacting the sample with a polypeptide of this invention and determining the amount of TGF-3 bound to the polypeptide.
  • This invention also provides methods of isolating TGF-/3 from a sample by contacting the sample with a polypeptide of this invention bound to a solid support to allow binding of TGF-3 to the polypeptide and isolating the TGF-3 from the polypeptide.
  • This invention also provides methods of enhancing the binding of TGF- ⁇ to a TGF- ⁇ receptor by contacting a cell bearing a TGF-3 receptor with TGF-/3 and a polypeptide of this invention.
  • This invention also provides methods of enhancing suppression of cell growth by TGF-/3 comprising contacting a cell with TGF-3 and a polypeptide of this invention.
  • compositions comprising a polypeptide of this invention in a pharmaceutically acceptable carrier.
  • This invention axso provides methods of treating a subject with a condition ameliorated by the enhanced binding of TGF-/3 to a TGF-3 receptor or by suppression of cell growth by TGF- ⁇ by administering a therapeutically effective amount of a pharmaceutical composition having a polypeptide of this invention.
  • This invention also provides decoy betaglycan polypeptides. It also provides methods of treating a subject with a condition ameliorated by the diminished binding of TGF-3 to a TGF- ⁇ receptor or by the inhibition of the suppression of cell growth by TGF-3 by administering to the subject a therapeutically effective amount of a pharmaceutical composition having a decoy betaglycan polypeptide. It also provides methods of suppressing TGF-/3-induced deposition of extracellular matrix in a subject by administering to the subject a therapeutically effective amount of a pharmaceutical composition having a decoy betaglycan polypeptide.
  • This invention also provides anti-betaglycan- binding-site antibodies. It also provides methods of treating a subject with a condition ameliorated by the diminished binding of TGF- ⁇ to a TGF- ⁇ receptor or by the inhibition of the suppression of cell growth by TGF- ⁇ by administering to the subject a therapeutically effective amount of a pharmaceutical composition having an anti- betaglycan-binding-site antibody of this invention. It further provides methods of suppressing TGF- ⁇ -induced deposition of extracellular matrix in a subject by administering to the subject a therapeutically effective amount of a pharmaceutical composition having an anti- betaglycan-binding-site antibody of this invention.
  • This invention also provides anti-idiotypic antibodies that mimic the ability of a polypeptide of this invention to bind TGF- ⁇ but that lack the biological function of enhancing binding of TGF- ⁇ to the type II receptor or enhancing suppression of cell growth by TGF- ⁇ . It also provides methods of treating a subject with a condition ameliorated by the diminished binding of TGF- ⁇ to a TGF- ⁇ receptor or by inhibition of the suppression of cell growth by TGF- ⁇ by administering to the subject a therapeutically effective amount of a pharmaceutical composition having an anti-idiotypic antibody of this invention. It also provides methods of suppressing TGF- ⁇ -induced deposition of extracellular matrix in a subject by administering to the subject a therapeutically effective amount of a pharmaceutical composition having an anti-idiotypic antibody of this invention.
  • Figures 1A and IB depict the coding region of rat betaglycan cDNA.
  • the filled part is the transmembrane region. Restriction sites used to generate the cDNA fragments are shown. The brackets show the cDNA fragments that were expressed as proteins (bgl through bg4) .
  • Figure IB depicts recombinant fragments of betaglycan analyzed by SDS-PAGE (4 % to 20 % gels) and Coomassie Blue staining.
  • Figures 2A and 2B present results of a competition assay for the binding of 125 I-TGF- ⁇ l to Hep G2 cells by betaglycan fragments.
  • Figure 3 shows gel electrophoresis of bg3 betaglycan fragments on the binding of 125 I-TGF- ⁇ to MV1 Lu cells in receptor affinity labeling.
  • MV1 Lu cells on 6-well dishes were affinity labeled by using 100 pM of 125 I-TGF- ⁇ l at 37°C without or with various concentrations of the bg3 fragment. After cross-linking the cells were solubilized and analyzed in SDS-PAGE followed by autoradiography.
  • the band at 71 kDa is RI
  • the bands at and below the 101 kDa marker represent RII
  • the wide band above the 208 kDa is betaglycan.
  • Figures 4A and 4B present results of binding studies of the bg3 betaglycan fragment to TGF- ⁇ l in a solid-phase binding assay.
  • 125 I-labeled bg3 fragment was incubated in microtiter wells coated with increasing concentrations of TGF- ⁇ l in the buffer (•) and in the presence of unlabeled bg3 fragment (0) (l ⁇ M).
  • 125 I-bg3 was incubated for the times indicated in microtiter wells coated with 1 ⁇ g/ml of TGF- ⁇ l. Binding is expressed as percent of the radioactivity added to the wells. Error bars show standard deviation of triplicate samples.
  • Figure 5A and 5B show competition and Scatchard plots for the binding of 125 I-bg3 betaglycan fragment to immobilized TGF- ⁇ l.
  • Figure 5A shows competition of 125 I- bg3 binding to TGF- ⁇ l by increasing concentrations of bg3 fragment.
  • Figure 5B shows Scatchard plot of the binding data in Figure 5A.
  • FIG. 6 shows results of a competition assay of the binding of 125 I-bg3 betaglycan fragment to immobilized TGF- ⁇ l by core proteins of decorin-type proteoglycans.
  • 125 I-bg3 was incubated in microtiter wells coated with TGF- ⁇ l (l ⁇ g/ml) in the presence of various concentrations of unlabeled bg3 fragment (O) or fusion proteins of human decorin ( ⁇ ) , human biglycan ( A ) , and human fibromodulin (•) core proteins, or maltose-binding protein ( ⁇ ), the protein the proteoglycan core proteins were fused to. Binding is expressed as a percent of binding of the 125 I-bg3 in the absence of competitors.
  • Figure 7 shows the effect of bg3 betaglycan fragment on TGF- ⁇ activity in MV 1 Lu cells.
  • MVl Lu assay was performed without (TGF- ⁇ -) or with (TGF- ⁇ +,0,1 ng/ml) added TGF- ⁇ and various concentrations of bg3 betaglycan fragment or an unrelated fusion protein prepared in the same way as bg3 as a control.
  • Figure 8 shows the specificity of the effect of the bg3 betaglycan fragment on TGF- ⁇ induced growth suppression.
  • MV 1 Lu assay was performed without or with TGF- ⁇ (0.1 ng/ml), bg3 (20 ⁇ g/ml) and neutralizing anti- TGF- ⁇ antibodies (20 ⁇ g/ml) as indicated in the figure.
  • Figures 9A and 9B depict the nucleotide sequence [SEQ ID N0:1] and deduced amino acid sequence [SEQ ID NO:2] of a cDNA encoding rat betaglycan.
  • Figure 10 depicts the nucleotide sequence [SEQ ID NO:3] and deduced amino acid sequence [SEQ ID NO:4] of a cDNA encoding human betaglycan.
  • This invention identifies, for the first time, a binding site in betaglycan for TGF- ⁇ .
  • Results of experiments reported herein demonstrate that a polypeptide containing about one-fourth of the extracellular domain of betaglycan closest to the cell membranei has the TGF- ⁇ binding site.
  • a polypeptide containing amino acids 543 to 769 of rat betaglycan [SEQ ID NO:2] contains this binding site. This polypeptide enhances the binding of TGF- ⁇ to the TGF- ⁇ type II receptor, enhances suppression of cell growth by TGF- ⁇ and competes with decorin-type proteoglycans for TGF- ⁇ binding.
  • sequence in reference to a polypeptide means the amino acid sequence of the polypeptide.
  • a sequence consists essentially of a sequence of a mammalian betaglycan if it corresponds, or corresponds except for minor modifications, to a portion of a sequence of a mammalian betaglycan.
  • minor modifications refers to simple substitutions, additions or deletions that do not eliminate the TGF- ⁇ binding capacity of the polypeptide or its ability to enhance TGF- ⁇ bioactivity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutation in hosts having DNA encoding these polypeptides. Simple substitutions include the substitution of an amino acid for another having a side chain off the alpha carbon of the same class, i.e. non-polar (hydrophobic) , neutral, positively charged or negatively charged.
  • the polypeptides of this invention have a sequence from a mammalian betaglycan and, in particular, from human, rat or pig betaglycan.
  • the nucleotide and amino acid sequences of rat betaglycan are given in Figures 9A-9B [SEQ ID N0S:1 and 2] and in Lopez-Casillas et al.. Cell , 67:785-95 (1991) (incorporated herein by reference) .
  • the nucleotide and amino acid sequences of human betaglycan are given in Figure 10 [SEQ ID NOS:3 and 4] and in Moren et al., Biochem. Biophys . Res . Coirnn. , 189:356-362 (1992) (incorporated herein by reference).
  • Polypeptides of this invention include those wherein the portion of a mammalian betaglycan is about one-fifth of the extracellular domain of a mammalian betaglycan closest to the cell membrane.
  • a one-hundred- fifty-five amino acid polypeptide having the sequence of amino acids 615-769 of SEQ ID NO:2 is one such polypeptide.
  • polypeptides of this invention include those wherein the portion of a mammalian betaglycan is about one-fourth of the extracellular domain of a mammalian betaglycan closest to the cell membrane.
  • the two-hundred-twenty-seven amino acid polypeptide having the sequence of amino acids 543-769 of SEQ ID NO:2 is one such polypeptide.
  • Polypeptides of this invention include those having sequences consisting essentially of a portion of the sequence of rat betaglycan [SEQ ID NO:2]. According to one embodiment of the invention, the polypeptide has a sequence consisting essentially of at least amino acids 615 to 769 of SEQ ID NO:2 to at most amino acids 501 to 769 of SEQ ID N0:2.
  • the polypeptide has a sequence consisting essentially of at least amino acids 543 to 769 of SEQ ID NO:2 to at most amino acids 501 to 769 of SEQ ID NO:2. All of these polypeptides include amino acids in a sequence shown to bind to TGF- ⁇ . They exclude polypeptides having the sequence that Lopez-Casillas et al.. Cell , 73:1435-44 (1993) asserted bind to TGF- ⁇ .
  • This invention is also directed to soluble polypeptides having the formula: A-B-C, wherein A is an amino acid sequence that excludes sequences of more than 4 amino acids from amino acids 1 to 501 of SEQ ID NO 1; B is a sequence consisting essentially of at least amino acids 543 to 769 of SEQ ID NO:2 to at most amino acids 501 to 769 of SEQ ID NO:2; and C is an amino acid sequence. In one embodiment of the invention, neither A nor C have more than 100 amino acids. Soluble polypeptides are those lacking a transmembrane region, the hydrophobic region of the polypeptide that anchors it in the cell membrane.
  • This invention is also directed to soluble polypeptides having the formula: A-B-C, wherein A is an amino acid sequence that excludes sequences of more than 4 amino acids from amino acids 1 to 543 of SEQ ID NO 1; B is at least 155 amino acids in a sequence consisting essentially of an amino acid sequence within amino acids 543 to 769 of SEQ ID NO:2; and C is an amino acid sequence. In one embodiment of this invention, neither A nor C have more than 100 amino acids.
  • polypeptides of this invention can be produced by synthesis on an automated peptide synthesizer, according to the manufacturer's instructions. For example, MODEL 430A, Applied Biosystems, Foster City, California, USA, is a synthesizer useful for this purpose.
  • the polypeptides of this invention can also be produced by the expression of a nucleic acid molecule that encodes the polypeptide. Methods for expressing the nucleic acids of this invention are described below.
  • Nucleic acid molecules of this invention can have nucleotide sequences for portions of rat or human betaglycan derived from Figures 9A-9B [SEQ ID NO:2] or Figure 10 [SEQ ID N0:4].
  • a nucleic acid having a sequence of at least nucleotides 1961 to 2641 and at most 1835 to 2641 of SEQ ID N0:1 encodes a polypeptide having a sequence of at least amino acids 543 to 769 of SEQ ID NO:2 to at most amino acids 501 to 769 of SEQ ID NO:2.
  • Nucleic acid molecules of this invention include degenerate versions of sequences of mammalian genes.
  • This invention is further directed to expression vectors having an expression control sequence operatively linked to a nucleic acid of this invention.
  • Expression vectors useful in this invention include plas ids, cosmids, phage and the like.
  • An expression control sequence is operatively linked to a nucleic acid molecule when it directs the transcription and translation of that molecule in an appropriate host cell. Expression vectors and their use are well known to the art.
  • This invention is further directed to prokaryotic and eukaryotic cells transfected with an expression vector of this invention and capable of expressing the nucleic acid of this invention.
  • the nucleic acids of this invention can be produced by organic synthesis on a commercial nucleic acid synthesizer or through PCR on a nucleic acid encoding a mammalian betaglycan.
  • Nucleic acid sequences encoding mammalian betaglycans can be identified by probing.cDNA libraries with probes derived from rat betaglycan [SEQ ID NO:l] or human betaglycan [SEQ ID NO:3] and by analyzing cDNA expression libraries with . ⁇ tibodies against betaglycan.
  • betaglycan from these mammals can be isolated and partially sequenced, and the sequence can be used to make sets of degenerate nucleic acid probes for probing gene libraries.
  • Other methods for identifying and isolating genes are also known.
  • nucleic acids, expression vectors and cells of this invention are useful for producing the polypeptides of this invention.
  • the nucleic acids of this invention also find use as probes for detecting a nucleic acid having a sequence encoding betaglycan.
  • the polypeptides of this invention find use in methods of detecting TGF- ⁇ in a sample. Since levels of TGF- ⁇ are altered upon injury or other pathologies, the level of TGF- ⁇ is a useful sign of these conditions.
  • the methods involve contacting the sample with a peptide of this invention and determining the amount of TGF- ⁇ bound to the polypeptide.
  • the well of a microtiter plate is coated with a polypeptide of this invention. The sample is added to the well and incubated under conditions to allow binding of TGF- ⁇ to the polypeptide. Unbound sample is removed.
  • the amount of TGF- ⁇ bound is determined by, for example, contacting the microtiter well with an anti- TGF- ⁇ antibody bound to a reporter group.
  • Reporter groups useful in this invention include chemiluminescent labels, fluorescent labels, radioactive labels, enzyme labels and the like. Variations on this method will be apparent to any person skilled in the art.
  • polypeptides of this invention find use in methods of isolating TGF- ⁇ from a sample by contacting the mixture with a peptide of this invention bound to a solid support to allow binding and isolating the TGF- ⁇ from the polypeptide.
  • a polypeptide of this invention is bound to an insoluble matrix and made into an affinity column.
  • the sample is passed over the column under conditions to allow the binding of TGF- ⁇ to the polypeptide. Unbound material is washed out of the column.
  • TGF- ⁇ is recovered by washing the column with a solution and under conditions that allow TGF- ⁇ to become unbound from the polypeptide. Variations on this method will be apparent to any person skilled in the art.
  • the polypeptides of this invention find use in methods of enhancing the binding of TGF- ⁇ to type II receptor. These methods involve, for example, contacting a cell bearing a type II receptor with TGF- ⁇ and a polypeptide of this invention.
  • This invention also provides methods of enhancing suppression of cell growth, particularly epithelial cell growth, by TGF- ⁇ . These methods involve, for example, contacting a cell with TGF- ⁇ and a polypeptide of this invention. Embodiments of these methods are described in the Example.
  • the polypeptides of this invention normally will be administered in a pharmaceutical composition.
  • the pharmaceutical compositions comprise the polypeptides of this invention in a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can further comprise TGF- ⁇ .
  • the term "pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate-buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. Suitable pharmaceutical carriers and their formulations are described in Martin, Remington 's Pharmaceutical Sciences , 15th Ed. (Mack Publishing Co., Easton 1975). Such compositions will, in general, contain a therapeutically effective amount of the polypeptide together with a suitable amount of carrier so as to prepare the proper dosage form for proper administration to the subject.
  • This invention provides methods of treating a subject with a condition ameliorated by the enhanced binding of TGF- ⁇ to type II receptor or by the enhanced suppression of cell growth by TGF- ⁇ by administering to the subject a therapeutically effective amount of a pharmaceutical composition having a polypeptide of this invention.
  • the pharmaceutical composition can further include TGF- ⁇ .
  • the term "therapeutically effective amount” is that amount necessary to alleviate the condition from which the subject suffers or prevent such a condition.
  • the term “subject” includes humans, other mammals or other vertebrates.
  • an effective amount of a polypeptide of this invention, including derivatives or salts thereof, or a pharmaceutical composition containing the same, as described above, is administered via any of the usual and acceptable methods known in the art, either singly or in combination with other pharmaceutical agents.
  • the particular dosage of pharmaceutical composition to be administered to the subject will depend on a variety of considerations including the nature of the disease, the severity thereof, the schedule of administration, -the age and physical characteristics of the subject, and so forth. Proper dosages may be established using clinical approaches familiar to the medicinal arts.
  • the pharmaceutical compositions can be administered via any of the usual and acceptable methods known in the art, for example orally, parenterally (e.g., intra-muscularly, intravenously, subcutaneously or locally to other tissues) or by inhalation, and in the form of solid or liquid dosage including tablets, suspensions, and aerosols.
  • decoy betaglycan polypeptides As used herein, a “decoy betaglycan polypeptide” is a polypeptide having a sequence correspondingEto at least a portion of a mammalian betaglycan ex ⁇ ept for disabling modifications to the amino acid sequence. As used herein, “disabling modifications” refers to simple substitutions, additions or deletions that allow retention of the TGF- ⁇ binding capacity of the polypeptide but that eliminate its ability to enhance TGF- ⁇ bioactivity, such as the binding of TGF- ⁇ to a TGF- ⁇ receptor, such as the TGF- ⁇ type II receptor, or the suppression of cell growth by TGF- ⁇ .
  • Disabling modifications also allow the decoy to suppress TGF- ⁇ bioactivity.
  • Decoy betaglycan polypeptides contain disabling modifications to betaglycan within the region known to enhance TGF- ⁇ bioactivity, that is, within about one- fourth of the extracellular domain of a mammalian betaglycan closest to the cell membrane and, in particular, to amino acids 543 to 769 of SEQ ID NO:2. These modifications can be introduced deliberately, as through site-directed mutagenesis.
  • Disabling modifications include, for example, the deletion of one or more amino acids, substitution of an amino acid for another having a different class of side chain off the alpha carbon, the elimination of a cysteine residue involved in disulfide bonding necessary for activity, the introduction of a proline or cysteine residue to alter the polypeptide's secondary structure and the like.
  • Decoy betaglycan polypeptides can be identified by introducing likely disabling modifications into the amino acid sequence and testing the resulting polypeptides for activity in any of the assays known to the art or described herein.
  • Decoy betaglycan polypeptides find use in detecting TGF- ⁇ in a sample and in isolating TGF- ⁇ from a sample. They also find use in methods of treating a subject with a condition ameliorated by the diminished binding of TGF- ⁇ to TGF- ⁇ receptor, by the inhibition of the suppression of cell growth by TGF- ⁇ , or the suppression of any other bioactivity of TGF- ⁇ .
  • decoy betaglycan polypeptides find use in suppressing TGF- ⁇ -induced deposition of extracellular matrix at a site of tissue injury.
  • glomerulonephritis diabetic nephropathy, lung fibrosis, liver cirrhosis, intimal hyperplasia, cardiac cirrhosis after infarct, adult respiratory distress syndrome and other fibrosis- related pathologies.
  • These methods involve administering to the subject a therapeutically effective amount of a pharmaceutical composition having a decoy betaglycan polypeptide of this invention.
  • This invention also provides anti-betaglycan- binding-site antibodies that eliminate the ability of betaglycan to enhance TGF- ⁇ bioactivity. This includes the binding of TGF- ⁇ to a TGF- ⁇ receptor, such as the
  • Anti-betaglycan-binding-site antibodies find use in detecting betaglycan in a sample and in isolating betaglycan from a sample. They also find use in methods of treating a subject with a condition ameliorated by the diminished binding of TGF- ⁇ to TGF- ⁇ receptor, by the inhibition of the suppression of cell growth by TGF- ⁇ , or the suppression of any other bioactivity of TGF- ⁇ .
  • anti-betaglycan binding site antibodies find use in suppressing TGF- ⁇ -induced deposition of extracellular matrix at a site of tissue injury.
  • glomerulonephritis diabetic nephropathy, lung fibrosis, liver cirrhosis, intimal hyperplasia, cardiac cirrhosis after infarct, adult respiratory distress syndrome and other fibrosis-related pathologies.
  • These methods involve administering to the subject a therapeutically effective amount of a pharmaceutical composition having an anti-betaglycan-binding-site antibody of this invention.
  • Anti-betaglycan-binding-site antibodies can be made by inoculating an animal with a polypeptide of this invention.
  • an aminal can be inoculated with a polypeptide having the sequence of amino acids 543 to 769 of rat betaglycan [SEQ ID NO:2].
  • An idiotype represents the specificity of an antibody for its ligand at the binding site.
  • An anti- idiotypic antibody is an antibody directed against the idiotype of another antibody. They are made by immunizing an animal with the other antibody. Anti- idiotypic antibodies can be made that have the internal image of the antigen against which the other antibody is directed and that mimic the binding characteristics of the antigen.
  • this invention is also directed to anti-idiotypic antibodies that mimic the ability of the polypeptides of this invention to bind TGF- ⁇ .
  • anti- idiotypic antibodies lack the biological function of betaglycan to enhance binding of TGF- ⁇ to the type II receptor or to enhance the suppression of cell growth by TGF- ⁇ . They also suppress other bioactivities of TGF- ⁇ .
  • Anti-idiotypic antibodies of this invention can be made by inoculating an animal with an anti-betaglycan-binding- site antibody of this invention. The anti-idiotypic antibodies of this invention find use in detecting TGF- ⁇ in a sample and in isolating TGF- ⁇ from a sample.
  • the methods involve administering to a subject a therapeutically effective amount of a pharmaceutical composition having an anti-idiotypic antibody of this invention.
  • the pBluescript SK(+) vector and XL1 Blue host cells were purchased from STRATAGENE® (La Jolla, California) .
  • the expression vectors, pQE8, 10, 11 and M15 host cells and Ni-NTA-agarose came from QIAGEN® (Chatsworth, California) , the buffer for PCR reactions from IDAHO TECHNOLOGY® (Idaho Falls, Idaho) and the Taq polymerase from BOEHRINGER MANNHEIM®.
  • GM 242 host cells were used in these experiments.
  • Other dam" cell lines for example, GM 48 or GM 163 cells (available from New England Biolabs, Beverly, Massachusetts) can also be used.
  • the purification kits for PCR fragments and for the plasmid were from PROMEGA® (Madison, Connecticut). All other cloning reagents were from INTERNATIONAL BIOTECHNOLOGIES INC.® (La Jolla, California) and BIORAD® (Richmond, California) .
  • TGF- ⁇ l is commercially available from Genzyme
  • DMEM Dulbecco's modified Eagle's medium
  • GIBCO® Gibco's modified Eagle's medium
  • carrier-free Na 125 I and 3 H- thymidine from NEW ENGLAND NUCLEAR® (Boston, Massachusetts)
  • IODO-GEN® from Pierce Chemical Co. (Rockford, Illinois).
  • IMMULON 2 REMOVAWELL® strips came from Dynatech Laboratories Inc. (Chantilly, Virginia), and CENTRICON® micro-concentrator from Amicon (Danvers, Massachusetts). All chromatographic materials including pre-packed PD-10 columns were from PHARMACIA® (Uppsala, Sweden) .
  • Neutralizing chicken anti-TGF- ⁇ antibody and normal chicken Ig were from R & D SYSTEMS® (Minneapolis, Minnesota) .
  • rat betaglycan The following segments from the DNA sequence of rat betaglycan [SEQ ID N0:1] were first amplified by PCR with appropriate tags for cloning purposes: nucleotides 404-1439 (A); nucleotides 1126-2268 (B) ; nucleotides 1712-3042 (C) ; and nucleotides 1961-2641 (D) (Lopez- Casillas et al.. Cell , 67: 785-95 (1991)). PCR reactions were performed on cDNA derived from rat smooth muscle cells using a MODEL 1605® Air Thermo-Cycler (Idaho Technology, Idaho Falls, ID) .
  • the fragments were ligated into the TA cloning site of the pBluescript SK vector (Marchuk et al., Nucl . Acids . Res . , 19:1154 (1990)) and the recombinant vector was transformed into XLl Blue.
  • the plasmid carrying PCR product B was re-transformed into GM 242 to recover a de ethylated Bel I site. All transformations were carried out using the CELL-PORATOR® (BRL, Gaithersburg, MD) electroporation system, and positive colonies were selected by the addition of isopropyl-b-D-thiogalactopyranoside (IPTG) and X-gal.
  • IPTG isopropyl-b-D-thiogalactopyranoside
  • X-gal isopropyl-b-D-thiogalactopyranoside
  • fragment bgl was excised by Bam HI digestion.
  • Fragment bg2 was obtained from product B by Bel I and Sal I digestion, and fragments bg3'N, bg3N and bg3C were prepared from product C by Bam HI, Bam HI and Xmn I, and Bam HI and Bgl II digestion, respectively.
  • Product D was designated bg3.
  • Fragments bgl, bg3, bg3 'N and bg3N were ligated into the Bam HI site of the pQE8 expression vector.
  • Fragments bg3C and bg4 were cloned into pQElO and bg2 into pQEll.
  • the vectors were transformed into M15 host cells by electroporation. Positive clones were selected by testing for the expression of the protein product.
  • the expression and purification of the bacterially expressed proteins were carried out according to instructions on page 16 of Qiagen's manual. Briefly, the expression was induced by 2 mM of IPTG and continued for 3 hr, after which the bacteria were lysed in 6 M guanidine-HCl, Tris buffer, pH 8. The supernatant was loaded onto a column of Ni-NTA resin, and the column was eluted with 8 M urea in Tris buffer, pH 4.5, after several washing steps. The protein solution was neutralized with 1 M Tris buffer, pH 9, containing 8 M urea.
  • the proteins were treated with dithiotreitol (50 °C for 30 min) and iodoacetamide (25 °C for 30 min) to reduce and alkylate cysteine residues.
  • dithiotreitol 50 °C for 30 min
  • iodoacetamide 25 °C for 30 min
  • the reaction mixture was loaded onto a PD-10 column equilibrated with 0.1 M ammonium bicarbonate containing 6 M urea. Elution of protein was monitored by protein assay (Bradford, Anal. Biochem. , 72:248-54 (1976)), and the main fraction was concentrated with CENTRICON 10®.
  • Competitors were dissolved in 6 M urea at 150-fold molar excess of solution. Final samples were prepared by diluting the sample 150-fold into assay buffer containing the 125 I-TGF- ⁇ l.
  • the following buffers were used: 25 mM Hepes, pH 7.4, 125 mM NaCl, 5 mM MgS0 4 , 5 mM KC1, 1 mM CaCl 2 , 2 mg/ml bovine serum albumin (BSA) ("binding buffer”); 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 % Triton X-100 ("solubilization buffer”); 10 mg/ml antipain, 10 mg/ml leupeptin, 2 mM benzamidine, 1 mM ethylenediamine- tetraacetic acid ("protease inhibitor cocktail,” final concentrations) .
  • BSA bovine serum albumin
  • Binding of 125 I-labeled proteins to immobilized TGF- ⁇ l was determined using a solid-phase binding assay (Mooradian et al., J. Cell . Biochem. , 41:189-200
  • 96-well IMMULON 2® plates were coated with 1 mg/ml TGF-bl (100 ml, 0.1 M carbonate buffer, pH 9.5) at 4 °C for 16 hr. The wells were blocked by incubating with the blocking buffer containing 2 % BSA, 0.005 % Tween 20, 0.02 % NaN 3 for 2 hr at 37 °C. An equal volume of varying concentrations of competitors, diluted in 6 M urea, was mixed in the assay buffer (same as the blocking buffer) containing the labeled proteins. Since the binding was found to be sensitive to urea, the final urea concentration was always kept under 100 mM. Duplicate 100 ml samples were incubated in the wells for 5rhr at 37 °C. After four washings with the same buffer, the bound radioactivity was measured in a Beckman Gamma- 4000 counter.
  • the mink lung epithelial cell growth inhibition assay was done as described (Danielpour et al., J. Cell . Physiol . , 138:79-86 (1989)). Briefly, cells were grown in Dulbecco's medium containing 10 % fetal calf serum, 10 mM L-glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin. For the experiments, the cells were plated on 96-well plates (20,000 cells/well) in the same medium. After one day the medium was replaced by Dulbecco's medium containing 1 % fetal calf serum with glutamine and antibiotics. The experiments were started the next day by adding the controls and effectors to the cells in the above medium.
  • the fusion proteins were dialyzed against assay medium. After 24 hours of incubation the cells were pulsed with 3 H-thymidine for 3 hours. The cells were fixed with methanol and extracted 3 times with 10 % trichloracetic acid, solubilized with 1 % SDS-0.3 N NaOH and the radioactivity was counted.
  • SDS-PAGE was performed according to Laemmli (Nature , 227:680-685 (1970)) using vertical precast gels.
  • the gels were fixed in 10 % isopropanol, 10 % acetic acid for 15 minutes and dried.
  • Kodak X-OMAT/AR® film with an enhancing screen was used for autoradiography.
  • Each of the pairs of PCR primers from the published rat betaglycan sequence generated a D ⁇ A fragment of the expected size.
  • Shorter D ⁇ A fragments were prepared from the primary PCR products as shown in Figure 1A and ligated into a vector that expresses the cloned protein as a fusion protein with a cassette of six histidines.
  • the expression system yielded 0.5 mg to 1.0 mg each of the betaglycan protein fragments from a 250 ml culture.
  • the bgl fragment contained a second band that may represent a fragment of the fusion protein; the other fusion protein products were essentially homogeneous.
  • Betaglycan fragments bgl, bg2 and bg3 were tested for their ability to inhibit the binding of 125 I- TGF-bl to Hep G2 cells; in these cells most of the specific binding of TGF- ⁇ is to betaglycan.
  • Hep G2 cells on 24-well dishes were incubated with 125 I-TGF- ⁇ l (100 pM) and with indicated concentrations of betaglycan fragments that had been expressed as fusion protein in bacteria. The bound TGF- ⁇ was measured. Ten percent of the total labeled protein bound to the cells in the absence of any competitor, and more than 90 % of this binding was displaced by the addition of 40 nM of unlabeled TGF- ⁇ l.
  • the bg3 fragment In affinity cross-linking of 125 I-TGF- ⁇ to the cell surface receptors of MV 1 Lu cells, the bg3 fragment enhanced the binding of TGF- ⁇ to the bands representing the type II receptor and to betaglycan itself at low concentrations (up to 50 nM) of the fragment. (Figure 3.) Higher concentrations competed for the binding of TGF- ⁇ to these binding sites.
  • the cross-linking of TGF- ⁇ to RI was unaffected by bg3 concentrations up to 500 nM, but higher concentrations appeared to be inhibitory.
  • TGF- ⁇ -binding betaglycan fragment The availability of the TGF- ⁇ -binding betaglycan fragment were used to study various parameters of its binding to TGF- ⁇ .
  • Figure 4A. The binding was inhibited by 1 mM of unlabeled bg3 fragment.
  • the binding of the bg3 fragment to TGF- ⁇ reached a maximum (about 25 % of total added) after 5 hours of incubation when 1 mg/ml of TGF- ⁇ l was used for the coating.
  • Figure 4B. The binding of the bg3 fragment to TGF- ⁇ reached a maximum (about 25 % of total added) after 5 hours of incubation when 1 mg/ml of TGF- ⁇ l was used for the coating.
  • the core proteins of extracellular matrix proteoglycans decorin, biglycan and fibromodulin bind TGF- ⁇ .
  • Solid-phase binding assay used to compare the TGF- ⁇ binding characteristics of these proteoglycans and betaglycan, showed that fusion proteins representing the core proteins of decorin, biglycan and fibromodulin each inhibited the binding of the bg3 betaglycan fragment to TGF- ⁇ , whereas the fusion partner, maltose-binding protein, showed no significant effect.
  • Figure 6. The 50 % inhibitory concentrations for the extracellular matrix proteoglycans were similar or slightly higher than for the betaglycan fragment. In a reverse experiment, the binding of labeled biglycan and fibromodulin core proteins to immobilized TGF- ⁇ l was inhibited by unlabeled betaglycan fragment.
  • the bg3 betaglycan fragment when administered together with a sub-maximally effective concentration of TGF- ⁇ l, enhanced the activity of TGF- ⁇ l in a concentration-dependent fashion.
  • the fragment alone had no effect on DNA synthesis of MV 1 Lu cells.
  • An unrelated fusion protein used as a negative control had no effect.
  • the TGF- ⁇ -promoting effect of bg3 could be blocked by adding neutralizing anti-TGF- ⁇ antibodies into the assay.
  • Figure 8. Non-immune IgG, which was used as a control, did not have this effect. >
  • endoglin and betaglycan share sequence similarities and bind to TGF- ⁇ in a similar manner
  • the region in betaglycan where we have localized the TGF- ⁇ binding site shows no apparent similarity with any part of endoglin.
  • the decorin-type proteoglycans also show no sequence similarity with betaglycan or endoglin.
  • the binding specificity of endoglin is different from that of betaglycan in that endoglin does not bind TGF- ⁇ 2, whereas betaglycan does. It may be that the sequence similarities in betaglycan and endoglin relate to shared functions of these molecules other than the TGF- ⁇ binding.
  • betaglycan and possibly also endoglin, is the modulation of TGF- ⁇ binding to the signal transduction receptors.
  • the active betaglycan fragment could increase the binding of TGF- ⁇ to the type II receptor in cell surface affinity labeling and that the fragment enhanced the bioactivity of TGF- ⁇ when added to cell cultures as a soluble protein.
  • the enhancement of the type II receptor binding is in agreement with the results of Lopez- Casillas et al. (1991), supra , who found that expression of recombinant betaglycan in a cell line that originally had little of it increased the TGF- ⁇ binding activity of the type II receptor.
  • NAME Campbell, Cathryn A.
  • MOLECULE TYPE DNA (genomic)
  • AAGCTACACC CGACTTGCCA CGATTGCCTT CAATCTGAAG AACCAAAGGC TGTTGGAGAG 240 ATG GCA GTG ACA TCC CAC CAC ATG ATC CCG GTG ATG GTT GTC CTG ATG 288 Met Ala Val Thr Ser His His Met He Pro Val Met Val Val Leu Met 1 5 10 15
  • TCT GTC ACC AAG GCT GAC CAA GAT CTG GGA TTC GCC ATC CAA ACC TGC 2160 Ser Val Thr Lys Ala Asp Gin Asp Leu Gly Phe Ala He Gin Thr cys 625 630 635 640
  • Val Leu lie Leu Lys Cys Lys Lys Ser Val Asn Trp Val He Lys Ser 275 280 285
  • MOLECULE TYPE DNA (genomic)
  • Gly Leu Asp Thr Leu Thr Val Met Gly lie Ala Phe Ala Ala Phe Val 780 785 790
  • GGG GAG ACA GCA GGA AGG CAG CAA GTC CCC ACC TCC CCG CCA GCC TCG 3099 Gly Glu Thr Ala Gly Arg Gin Gin Val Pro Thr Ser Pro Ala Ser 815 820 825

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des polypeptides qui se fixent au TGF-β et ont une séquence d'acides aminés d'une partie d'un bétaglycane de mammifère. Ces polypeptides amplifient l'activité de fixation du TGF-β au récepteur de type II, ainsi que l'activité de suppression de croissance cellulaire par le TGF-β. Cette invention se rapporte également à des molécules isolées d'acide nucléique codant ces polypeptides, à des procédés de détection et d'isolation du TGF-β, à des composition pharmaceutiques contenant ces peptides ainsi qu'à l'utilisation thérapeutique de celles-ci. Cette invention se rapporte encore à des polypeptides leurres du bétaglycane, à des anticorps du site de liaison d'un anti-bétaglycane, ainsi qu'à des anticorps anti-idiotypiques dirigés contre un anti-bétaglycane. L'invention se rapporte enfin aux utilisations de ces compositions.
PCT/US1994/011648 1993-10-15 1994-10-14 POLYPEPTIDES DE BETAGLYCANE DOTES D'UNE ACTIVITE DE FIXATION AU FACTEUR DE CROISSANCE TRANSFORMANT DE TYPE BETA TGF-$g(b) WO1995010610A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU80168/94A AU8016894A (en) 1993-10-15 1994-10-14 Betaglycan polypeptides having tgf-beta binding activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13836893A 1993-10-15 1993-10-15
US08/138,368 1993-10-15

Publications (2)

Publication Number Publication Date
WO1995010610A1 true WO1995010610A1 (fr) 1995-04-20
WO1995010610A9 WO1995010610A9 (fr) 1995-06-22

Family

ID=22481710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/011648 WO1995010610A1 (fr) 1993-10-15 1994-10-14 POLYPEPTIDES DE BETAGLYCANE DOTES D'UNE ACTIVITE DE FIXATION AU FACTEUR DE CROISSANCE TRANSFORMANT DE TYPE BETA TGF-$g(b)

Country Status (2)

Country Link
AU (1) AU8016894A (fr)
WO (1) WO1995010610A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0669833A1 (fr) * 1992-10-29 1995-09-06 Celtrix Pharmaceuticals, Inc. UTILISATIONS D'UN FRAGMENT DE RECEPTEUR DU TGF-$g(b) COMME AGENT THERAPEUTIQUE
WO1997005892A1 (fr) * 1995-08-04 1997-02-20 The Victoria University Of Manchester Utilisation de betaglycanne pour obtenir une cicatrice reduite
EP1237565A1 (fr) * 1999-12-15 2002-09-11 Research Development Foundation Betaglycane utilise comme recepteur de l'inhibine et ses utilisations
WO2005028517A2 (fr) * 2003-05-09 2005-03-31 The General Hospital Corporation PROTEINES DE FUSION SOLUBLES DU RECEPTEUR TGF- ss DE TYPE III
WO2004100864A3 (fr) * 2003-05-13 2005-12-15 Univ Mexico Nacional Autonoma Kit de traitement utilise conjointement a une antibiotherapie pour le traitement de maladies infectieuses intracellulaires
WO2006061628A1 (fr) 2004-12-08 2006-06-15 Ares Trading S.A. Recepteur de proteines de type tgr3
EP2230252A1 (fr) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation de la thromborésistance endothéliale
WO2012090997A1 (fr) 2010-12-27 2012-07-05 京都府公立大学法人 CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION
WO2013014262A1 (fr) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de diagnostic et de traitement du syndrome de myhre
WO2013100208A1 (fr) 2011-12-28 2013-07-04 京都府公立大学法人 Normalisation d'une culture de cellules endothéliales de la cornée
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
EP2862867A2 (fr) 2005-10-25 2015-04-22 The Johns Hopkins University Procédés et compositions pour le traitement du syndrome de Marfan et troubles associés
WO2015064768A1 (fr) 2013-10-31 2015-05-07 京都府公立大学法人 Médicament thérapeutique pour des maladies associées à la mort cellulaire du réticulum endoplasmique dans l'endothélium de la cornée
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
WO2020201362A2 (fr) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010215A1 (fr) * 1991-11-15 1993-05-27 Memorial Sloan-Kettering Cancer Center Proteaglicane betaglycane purifiee, compositions et procedes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010215A1 (fr) * 1991-11-15 1993-05-27 Memorial Sloan-Kettering Cancer Center Proteaglicane betaglycane purifiee, compositions et procedes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUKUSHIMA D;BUTZOW R;HILDEBRAND A;RUOSLAHTI E;: "Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans.", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 268, no. 30, 25 October 1993 (1993-10-25), BALTIMORE US, pages 22710 - 22715 *
MASSAGUÉ, J. ET AL.;: "TGF-beta receptors", MOLECUCLAR REPRODUCTION AND DEVELOPMENT, vol. 32, no. 2, June 1992 (1992-06-01), pages 99 - 104 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0669833A1 (fr) * 1992-10-29 1995-09-06 Celtrix Pharmaceuticals, Inc. UTILISATIONS D'UN FRAGMENT DE RECEPTEUR DU TGF-$g(b) COMME AGENT THERAPEUTIQUE
EP0669833A4 (fr) * 1992-10-29 1996-07-31 Celtrix Pharma UTILISATIONS D'UN FRAGMENT DE RECEPTEUR DU TGF--g(b) COMME AGENT THERAPEUTIQUE.
US5693607A (en) * 1992-10-29 1997-12-02 Segarini; Patricia R. Uses of TGF-β receptor fragment as a therapeutic agent
WO1997005892A1 (fr) * 1995-08-04 1997-02-20 The Victoria University Of Manchester Utilisation de betaglycanne pour obtenir une cicatrice reduite
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
US6060460A (en) * 1995-08-04 2000-05-09 The Victoria University Of Manchester Use of betaglycan to reduce scarring
US7455839B2 (en) 1999-12-15 2008-11-25 Research Development Foundation Method of inhibiting the formation of inhibin/betaglycan complexes with an anti-betaglycan antibody
EP1237565A4 (fr) * 1999-12-15 2003-05-21 Res Dev Foundation Betaglycane utilise comme recepteur de l'inhibine et ses utilisations
EP1237565A1 (fr) * 1999-12-15 2002-09-11 Research Development Foundation Betaglycane utilise comme recepteur de l'inhibine et ses utilisations
WO2005028517A2 (fr) * 2003-05-09 2005-03-31 The General Hospital Corporation PROTEINES DE FUSION SOLUBLES DU RECEPTEUR TGF- ss DE TYPE III
WO2005028517A3 (fr) * 2003-05-09 2005-11-03 Gen Hospital Corp PROTEINES DE FUSION SOLUBLES DU RECEPTEUR TGF- ss DE TYPE III
WO2004100864A3 (fr) * 2003-05-13 2005-12-15 Univ Mexico Nacional Autonoma Kit de traitement utilise conjointement a une antibiotherapie pour le traitement de maladies infectieuses intracellulaires
WO2006061628A1 (fr) 2004-12-08 2006-06-15 Ares Trading S.A. Recepteur de proteines de type tgr3
EP2862867A2 (fr) 2005-10-25 2015-04-22 The Johns Hopkins University Procédés et compositions pour le traitement du syndrome de Marfan et troubles associés
EP2230252A1 (fr) 2006-03-13 2010-09-22 The Johns Hopkins University Augmentation de la thromborésistance endothéliale
EP3254696A1 (fr) 2006-10-03 2017-12-13 Genzyme Corporation Utilisation d'antagonistes de tgf-bêta pour traiter des nourrissons risquant de développer une dysplasie broncho-pulmonaire
EP2918288A1 (fr) 2006-10-03 2015-09-16 Genzyme Corporation Utilisation d'antagonistes de TGF-BETA pour traiter des nourrissons risquant de développer une dysplasie broncho-pulmonaire
US8642034B2 (en) 2006-10-03 2014-02-04 Genzyme Corporation Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
WO2012090997A1 (fr) 2010-12-27 2012-07-05 京都府公立大学法人 CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION
WO2013014262A1 (fr) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de diagnostic et de traitement du syndrome de myhre
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
US9925154B2 (en) 2011-10-26 2018-03-27 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
WO2013100208A1 (fr) 2011-12-28 2013-07-04 京都府公立大学法人 Normalisation d'une culture de cellules endothéliales de la cornée
EP3553169A1 (fr) 2011-12-28 2019-10-16 Kyoto Prefectural Public University Corporation Normalisation de culture de cellules endothéliales cornéennes
WO2015064768A1 (fr) 2013-10-31 2015-05-07 京都府公立大学法人 Médicament thérapeutique pour des maladies associées à la mort cellulaire du réticulum endoplasmique dans l'endothélium de la cornée
EP3804760A1 (fr) 2013-10-31 2021-04-14 Kyoto Prefectural Public University Corporation Médicament thérapeutique pour des maladies liées à la mort cellulaire du réticulum endoplasmique dans l'endothélium cornéen
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2020201362A2 (fr) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de prédiction et de prévention du cancer chez des patients ayant des lésions prémalignes

Also Published As

Publication number Publication date
AU8016894A (en) 1995-05-04

Similar Documents

Publication Publication Date Title
US6855808B2 (en) Proteins and methods for producing the proteins
AU714107B2 (en) Neurturin and related growth factors
AU743490B2 (en) NTN-2 member of TNF ligand family
US6919434B1 (en) Monoclonal antibodies that bind OCIF
US5705609A (en) Decorin fragments inhibiting cell regulatory factors
AU7608898A (en) Ntn-2 member of tnf ligand family
WO1995010610A1 (fr) POLYPEPTIDES DE BETAGLYCANE DOTES D'UNE ACTIVITE DE FIXATION AU FACTEUR DE CROISSANCE TRANSFORMANT DE TYPE BETA TGF-$g(b)
WO1995010610A9 (fr) POLYPEPTIDES DE BETAGLYCANE DOTES D'UNE ACTIVITE DE FIXATION AU FACTEUR DE CROISSANCE TRANSFORMANT DE TYPE BETA TGF-$g(b)
BG65519B1 (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
JP2001157593A (ja) 哺乳動物ケモカインｃｃｆ１８およびレセプターｃｃｋｒ３
WO1991010727A1 (fr) Inhibiteurs de facteurs regulateurs cellulaires
CA2299619A1 (fr) Nouveau recepteur orphelin
EP0886651A1 (fr) Persephine et facteurs de croissance associes
EP1105477A1 (fr) Dcr5, proteine de fixation de proteines morphogenetiques osseuses, et ses applications
EP0636175A1 (fr) Fragments de decorine et procede d'inhibition de facteurs de regulation cellulaire
AU2207999A (en) Novel nucleic acid and polypeptide
EP0700401A1 (fr) Capteur de calcium chez l'homme
CA2334042A1 (fr) Recepteur de cytokine orphelin
JP2004000237A (ja) 新規蛋白質及びその製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ FI GE HU JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/11-11/11,DRAWINGS,REPLACED BY NEW PAGES 1/16-16/16;DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA